A single injection of a novel CRISPR gene-editing treatment safely and efficiently removes SIV – a virus related to the AIDS-causing agent HIV – from the genomes of non-human primates, scientists at the Lewis Katz School of Medicine at Temple University now report. The groundbreaking work, published online in the journal Gene Therapy, complements previous experiments as the basis for the first-ever clinical trial of an HIV gene-editing technology in human patients, which was authorized by the Food and Drug Administration (FDA) in 2022. The study is led by co-corresponding authors Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Microbiology, Immunology, and Inflammation at the Lewis Katz School of Medicine at Temple University, and Tricia H. Burdo, PhD, Professor and Vice Chair in the Department of Microbiology, Immunology, and Inflammation at the Katz School of Medicine. ScienceDaily and BioBuzz provided continuing coverage.
Weather Alert: A major winter storm is likely to impact the Philadelphia region this weekend into Monday. Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH